Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEPAC-TDM: PK-guided Paclitaxel in NSCLC
NCT01326767Phase 3Completed
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Mar 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of paclitaxel in non-small cell lung carcinoma (NSCLC), sponsored by Central European Society for Anticancer Drug Research. Started Mar 2011; status: completed.
02
Drugs
paclitaxel
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT01326767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01326767.